Oral Pancreatic Cancer Vaccine V3-P

**Semantic type:** Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance

**Definition:** An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.

**Synonyms:** - Cancer Vaccine V3-P - Oral Tableted Therapeutic Vaccine V3-P - V3 P - V3-P - V3-P Cancer Vaccine - V3P